BackIterum Therapeutics Plc Overview

Iterum Therapeutics Plc Total Revenue

Track Iterum Therapeutics Plc's total revenue ($390K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$390000.00

As of Sep 2025

Annual Revenue (TTM)

$390000.00
↓ 85.11% YoY

Trailing 12 months ending Sep 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Iterum Therapeutics Plc (ITRM) FAQ

Iterum Therapeutics Plc (ITRM) currently reports a total revenue of $390K as of September 2025. That compares with $2.6M in the prior-year period — down 85.1% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Iterum Therapeutics Plc's total revenue history and peer comparisons.

Iterum Therapeutics Plc's total revenue decreased from $2.6M to $390K — a 85.1% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Iterum Therapeutics Plc's total revenue of $390K is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Iterum Therapeutics Plc reported $390K in total revenue as of September 2025. That compares with $2.6M in the prior-year period — down 85.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $390K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Iterum Therapeutics Plc, and consider following ITRM for alerts when major investors trade the stock.